StockData

Cryoport vs Ligand Pharmaceuticals

CYRX and LGND side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CYRX and LGND compare

Ligand Pharmaceuticals is the larger company, worth 5.9 times as much as Cryoport ($5.9B against $1000M).

Cryoport grew revenue faster over the last twelve months (12.1% versus 1.0% for Ligand Pharmaceuticals).

Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −20.1% at Cryoport.

Cryoport scores higher on the StockData Score (11 against 6 for Ligand Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCYRXLGND
Size and price
Market cap$1000M$5.9B
Share price$19.74$293.81
Change, 1 year128%46.3%
Change, 5 years−70.3%87.3%
Beta (5Y)1.430.84
Employees73847
StockData Score
Total score11 (better)6
Valuation score1 (better)0
Growth score3 (better)1
Performance score33
Health score4 (better)2
Dividend score00
Valuation
P/E–128×
P/S5.4× (better)23.2×
P/B2.0× (better)6.1×
EV/EBITDA–108×
P/FCF–64.8×
FCF yield−2.0%1.5% (better)
Fair value$16.22$55.15
Margin of safety−21.7% (better)−433%
Growth
Revenue growth (TTM)12.1% (better)1.0%
Revenue growth, 5Y average17.5% (better)10.4%
Net income growth (TTM)−147%5.9% (better)
EPS growth (TTM)−164%18.7% (better)
Profitability
Gross margin47.1%–
Operating margin−21.2%10.1% (better)
Net margin−20.1%20.3% (better)
FCF margin−10.7%35.7% (better)
Return on equity−7.4%5.4% (better)
Return on invested capital−33.0%2.6% (better)
Financial health
Debt / equity0.00 (better)1.17
Net debt / EBITDA–11.26
Interest coverage−18.8×3.1× (better)
Current ratio2.08 (better)1.22
Altman Z-score1.403.32 (better)
Piotroski F-score56 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions93.9%113%
Held by insiders3.6%2.6%
Insider net buying, 12 months−$6.3M (better)−$36.5M
Short interest, % of float7.1%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.